1. Home
  2. SGLY vs INDP Comparison

SGLY vs INDP Comparison

Compare SGLY & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGLY
  • INDP
  • Stock Information
  • Founded
  • SGLY 2001
  • INDP 2000
  • Country
  • SGLY United States
  • INDP United States
  • Employees
  • SGLY N/A
  • INDP N/A
  • Industry
  • SGLY
  • INDP Biotechnology: Pharmaceutical Preparations
  • Sector
  • SGLY
  • INDP Health Care
  • Exchange
  • SGLY Nasdaq
  • INDP Nasdaq
  • Market Cap
  • SGLY 3.9M
  • INDP 6.0M
  • IPO Year
  • SGLY 2008
  • INDP N/A
  • Fundamental
  • Price
  • SGLY $1.11
  • INDP $11.00
  • Analyst Decision
  • SGLY
  • INDP Strong Buy
  • Analyst Count
  • SGLY 0
  • INDP 2
  • Target Price
  • SGLY N/A
  • INDP $8.50
  • AVG Volume (30 Days)
  • SGLY 53.3K
  • INDP 689.8K
  • Earning Date
  • SGLY 08-26-2025
  • INDP 08-11-2025
  • Dividend Yield
  • SGLY N/A
  • INDP N/A
  • EPS Growth
  • SGLY N/A
  • INDP N/A
  • EPS
  • SGLY N/A
  • INDP N/A
  • Revenue
  • SGLY $2,172,036.00
  • INDP N/A
  • Revenue This Year
  • SGLY N/A
  • INDP N/A
  • Revenue Next Year
  • SGLY N/A
  • INDP N/A
  • P/E Ratio
  • SGLY N/A
  • INDP N/A
  • Revenue Growth
  • SGLY N/A
  • INDP N/A
  • 52 Week Low
  • SGLY $0.54
  • INDP $7.56
  • 52 Week High
  • SGLY $7.65
  • INDP $66.64
  • Technical
  • Relative Strength Index (RSI)
  • SGLY 59.35
  • INDP 51.26
  • Support Level
  • SGLY $0.93
  • INDP $9.45
  • Resistance Level
  • SGLY $1.10
  • INDP $13.44
  • Average True Range (ATR)
  • SGLY 0.08
  • INDP 2.06
  • MACD
  • SGLY -0.01
  • INDP 0.19
  • Stochastic Oscillator
  • SGLY 78.26
  • INDP 28.75

About SGLY Singularity Future Technology Ltd.

Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: